TTX
TTRATHERIX FPO [TTX]
Healthcare · ASX Small Cap
$5.0900 +22.4%
Updated 17 Mar 2026 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +0First seen: 2026-03-16
Score Breakdown
Technical81
Catalyst50
Sentiment50
Fundamental86
Momentum75
Risk Gate50
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Pressing against the upper Bollinger Band — extended and may need to cool off
- Trading above both moving averages — the trend is your friend here
- Volume surging at 3.9x normal while price climbs — real buying conviction behind this move
- Just broke above 20-day resistance — a level that was capping price, now cleared
- On a tear — up 27.3% over the last 5 days
- Beating the Small Ords index — relative strength of 1.42, so it's outpacing the pack
- Volatility is expanding fast — choppy price action, so buckle up
- Strong cash runway (13 quarters)
- Very high P/S ratio (146.1x)
- Strong revenue growth (+206%)
- EPS estimates revised upward (+10pts)
- Near 52-week high (100% of range)
- CANSLIM N: Near 52-week high (breakout territory)
- CANSLIM S: Tight float (20%)
- Sentiment is mixed — no strong consensus either way
- Positive long-term momentum — up 28% over the past year
- Revenue growing at +206% — the top line is moving in the right direction
- The bigger volume days are the up days — volume-weighted momentum is positive (3.89%/day)
- RBA hiking (-3pts)
- Overseas risk_off (-3pts, S&P500 down, VIX 24)
Risk Signals
- RSI is running hot — overbought territory, so expect some pullback risk
- Stochastic turning bearish from a high level — caution
- RSI is overbought but volume confirms it — this could be genuine momentum, not just froth
- Not enough chatter to gauge sentiment — defaulting to neutral
- ASX200 bearish (-1.3% 5d)
Recent Catalysts
NONE Precision medicine franchise launch and new revenue
NONE Tutelix Update
NONE HY FY26 Letter
Recent ASX Announcements
| 2026-03-15 | Precision medicine franchise launch and new revenue PRICE SENSITIVE |
| 2026-03-09 | Tutelix Update PRICE SENSITIVE |
| 2026-02-24 | HY FY26 Letter |
| 2026-02-23 | Half Yearly Report and Accounts PRICE SENSITIVE |
| 2026-02-16 | TetraDerm Cohort 1 Results PRICE SENSITIVE |
Key Metrics
$291.9M
Market Cap
11K
Avg Volume
3.9x
Vol Ratio
$2.88 — $5.75
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-150.0%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | pass | Near 52w High |
| S | Supply & Demand | pass | Float: 20% |
| L | Leader vs Laggard | pass | RS: 14 |
| I | Institutional Sponsorship | weak | Inst: 2% |
| M | Market Direction | caution | Bearish |
Sector: Healthcare
Ranked #56 of 120 · Sector avg: 36
View all Healthcare signals →